Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.
Status:
Completed
Trial end date:
2021-06-18
Target enrollment:
Participant gender:
Summary
To characterize the safety and tolerability of NIS793 as single agent and in combination with
PDR001 and to identify recommended doses for future studies.